Contrary to the classical view of the hair cycle, in which telogen is the resting phase that precedes the release of the hair shaft, another phase has been introduced, exogen. Exogen is the phase wherein the processes for the release of the hair shaft are initiated and successfully executed. Exogen ends when the shaft is liberated. Accordingly, human hairs would be preferably released not with telogen but with exogen roots. To better understand this somehow revolutionary point and what occurs in telogen effluvium (TE) and in androgenetic alopecia (AGA), we undertook a morphological study. We examined 25 women of comparable age by collecting shedding hairs by the Modified Wash Test under stringent diagnostic criteria. Eight patients were “normal”, 5 had AGA, 9 TE, and 3 had a TE+AGA overlap. Hair roots were divided into early telogen, full telogen, and exogen. Exogens accounted, in normal women, for 2.6% of all hairs, for 5.2% in AGA, for 6.6% in TE, and for 2.3% in TE+AGA, without any significant difference. Our exogen prevalence (2.6%) did not vary in patients with AGA and TE. Therefore, the pathogenetic role of exogen in AGA and TE seems negligible.

Keywords:
Hair loss, Alopecia, Telogen effluvium, Androgenetic alopecia, Exogen
1.
Stenn K: Exogen is an active, separately controlled phase of the hair growth cycle. J Am Acad Dermatol 2005;52:374-375.
2.
Milner Y, Sudnik J, Filippi M, Kizoulis M, Kashgarian M, Stenn K: Exogen, shedding phase of the hair growth cycle: characterization of a mouse model. J Invest Dermatol 2002;119:639-644.
3.
Savill A: The hair and scalp. A clinical study. Edward Arnold & Co. (ed), London, 1952, ed 4, p 11.
4.
Van Neste D, Leroy T, Conil S: Exogen hair characterization in human scalp. Skin Res Technol 2007;13:436-443.
5.
Rebora A, Guarrera M, Baldari M, Vecchio F: Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method. Arch Dermatol 2005;141:1243-1245.
6.
Rushton DH: Management of hair loss in women. Dermatol Clin 1993;11:47-53.
7.
Guarrera M, Cardo PP, Rebora A: Assessing the reliability of the Modified Wash Test. G Ital Dermatol Venereol 2011;146:289-294.
8.
Rebora A: Proposing a simpler classification of telogen effluvium. Skin Appendage Disord 2016;2:35-38.
9.
Loussouarn G, Lozano I, Panhard S, Collaudin C, El Rawadi C, Genain G: Diversity in human hair growth, diameter, colour and shape. An in vivo study on young adults from 24 different ethnic groups observed in the five continents. Eur J Dermatol 2016;26:144-154.
10.
Wilson E: Healthy skin. A popular treatise on the skin and hair. Their preservation and management. Blanchard & Lea, Ed., Philadelphia, 1854, 2nd Am. edition, p 87.
11.
Tellez-Segura R: Involvement of Mechanical Stress in Androgenetic Alopecia. Int J Trichology 2015;7:95-99.
12.
Higgins CA, Westgate GE, Jahoda CA: Modulation in proteolytic activity is identified as a hallmark of exogen by transcriptional profiling of hair follicles. J Invest Dermatol 2011;131:2349-2357.
13.
Rebora A, Guarrera M: Kenogen. A new phase of the hair cycle? Dermatology 2002;205:108-110.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.